2nd World Congress of Vaccine-2010, Beijing, China

[Guest guest]

get this email address!

From: " Grace " <grace@...>

vaccinecon - pretty much covers it..............

Sheri

BIT Life Sciences' 2nd World Congress of Vaccine

Theme: Next Generation Vaccines

Time: March 24th-26th, 2010

Venue: Beijing International Convention Center, Beijing,

China

Website:

http://www.bitlifesciences.com/wcv2010

Dear Dr. wwithin,

BIT Life Sciences' 2nd Annual World Congress of Vaccine 2010, with

a theme of " Next Generation Vaccines� which will be held

during March 24th-26th, 2010 at Beijing International

Convention Center, China. The Congress will be the largest meeting

devoted exclusively to the research on vaccines and will be associated

with technologies of infectious and non-infectious diseases in China.

At present, more than 300 core researchers & senior scholars working

in the field of Vaccine have confirmed to participate in the scientific

program; their presentations and papers will provide delegates with

information on the recent developments in the field of vaccine and

present the latest products and technologies. We sincerely hope more and

more experts can join us and witness the advances in Novel Vaccines

together. For more information, please visit the website

http://www.bitlifesciences.com/wcv2010 .

The breathtaking and ambitious program includes:

Track 1: Basic Vaccinology and Modern Vaccine Discovery Technologies

Track 2: Human Vaccines: Major Infectious Diseases

Track 3: Human Vaccine: AIDS Vaccine

Track 4: Human Vaccines: Non-Infectious Diseases

Track 5: Human Vaccines:-Cancer Vaccines

Track 6: Public Health, Economics, Safety/Ethic and Regulatory

Aspects

Track 7: Livestock/Veterinary/ Aquaculture Vaccine R & D

Track 8: Vaccine Bioprocessing, Production and Manufacturing

Renowned Speakers:

Dr. Roy Curtiss III, Academician, United States National

Academy of Sciences, USA

Dr. B. Robbins, Senior Investigator, National Institute of

Health, 1996 Albert Lasker Medical Award Winner, USA

Dr. Kiselev Oleg, Academician, Russian Academy of Medical

Sciences, Russia

Dr. Dexian Zheng, Vice President, Chinese Society for Immunolgy,

China

Dr. Almond, Vice President, Global Research and External

Research and Development, Sanofi-Pasteur, France

Dr. Jean- Prieels, Senior Vice President, Research &

Development, GlaxoKline Biologicals, Belgium

Dr. H. Khoury, Vice President, Global Marketing Baxter

BioScience, Vaccines, USA

Dr. Nathalie Garcon, Vice President , Head of Global Adjuvant

Center for Vaccines, GSK Biologicals, USA

Dr. Eszter Nagy, Vice President, Intercell AG, Austria

Dr. Jean-Yves Bonnefoy, Chief Scientific Officer, Transgene S.A,

France

Dr. Nathalie Landry, Vice President, Product Development, Medicago

Inc, Canada

Dr. Alan Korman, Vice President, Discovery Research, Medarex, USA

Dr. Scherman, Professor & Director, INSERM,

France

Dr. Louis-P. Vézina, Chief Scientific Officer, Medicago Inc,

Canada

Dr. ph Saba, CEO, AXIO International, France

Dr. M. Galarza, CEO & President, TechnoVax, Inc.,

USA

Dr. Bernd Eisele, CEO, VPM Inc, Germany

Dr. Lockhart, Senior Vice President, Product Development,

Emergent BioSolutions, UK

Dr. Malcolm , President and CEO, Arbovax, Inc, USA

Dr. Grayson Lipford, Vice President, Selecta

Biosciences Inc., USA

Dr. M. Y. Lim, Vice President Asia Region, BIA

Separations, Austria

Dr . B. Ulmer, Global Head, External Research, Novartis

Vaccines, UK

Dr. Wenyan Shen, Executive Director and Head, Biologics

Research & GlycoFi, Merck & Co., Inc., USA

Dr. O. Favorov, Director of Translational Research

Division, International Vaccine Institute, Korea

Dr. Liu, Director, Vaccine Development, MedImmune,

USA

Dr. Washabaugh, Senior Director, Merck Research

Laboratories, Merck & Co., Inc., USA

Do not hesitate to join us! Look forward to seeing you in Beijing,

China.

Sincerely yours,

Program Coordinator

Organizing Committee of WCV

26 Gaoneng St., R401

Dalian Hightech Zone

Dalian, LN 116025, China

Tel: 0086-411-84799479

Fax: 0086-411-84799629

E-mail: monica@...

Full Program

Keynote Presentations and Plenary Lectures-

Creation of a Better World

Session Chair: Dr. Liangzhi Xie, President and CEO, Sino Biological Inc.,

Professor, Peking Union Medical College, China

09:40-10:00 Title: New Technologies in Using Recombinant Attenuated

Salmonella Vaccine Vectors

Dr. Roy Curtiss III, Academician, United States National Academy of

Sciences, USA

10:00-10:20 Title: Four New Vaccines from the NIH

Dr. B Robbins, Senior Investigator, National Institute of Health,

1996 Albert Lasker Medical Award Winner, USA

10:20-10:40 Title: Death Receptor–Targeted Antibody Therrapy for Cancer

And Chronic Deseases

Dr. Dexian Zheng, Vice President, Chinese Society for Immunolgy,

China

10:40-11:00 Title: Discovery Research in the Vaccines Industry : How to

Organize for Maximum Impact

Dr. Almond, Vice President, Global Research and External Research

and Development, Sanofi-Pasteur, France

11:00-11:20 Title: Next Generation Vaccines

Dr. Jean- Prieels, Senior Vice President, Research & Development,

GlaxoKline Biologicals, Belgium

11:20-11:40 Title: The Future of the Vaccines Industry: New Targets and

New Markets

Dr. H. Khoury, Vice President, Global Marketing Baxter BioScience,

Vaccines, USA

11:40-12:00 Title: Principal Considerations for Developing Successful

Therapeutic Antibodies

Dr. Wenyan Shen, Executive Director and Head, Biologics Research

& GlycoFi, Merck & Co., Inc., USA

Track 1: Basic Sciences of Preclinical Studies

　-Sciences is All We Need to Start

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

13:30-14:20 Track 1-1: Infectious Immunology, Immunity

and Vaccinology

Chair: Dr. Eskild sen, Principal

Investigator, Aarhus University Hospital �Skejby, Denmark

13:30-13:55 Title: Chinese HB Vaccine R & D and

Production

Dr. Yan Wang, Professor, Shenzhen Polytechnic, China

13: 55-14:20 Title: Antibody-Mediated Protective Immunity

against Intracellular Bacterial Pathogens

Dr. Guoquan Zhang, Assistant Professor, University of Missouri-Columbia,

USA

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

14:20-15:10 Track 1-2: Advanced Cell Biology and

Molecular Biology in Vaccine Development

Chair: Dr. Eskild sen, Principal

Investigator, Aarhus University Hospital �Skejby, Denmark

14:20-14:45 Title: Toxoplasma Gondii: a Model Organism

for Development of Vaccines against Apicomplexan Protozoan Parasites

Dr. Eskild sen, Principal Investigator, Aarhus University Hospital

� Skejby, Denmark

14:45-15:10 Title: Blood Dendritic Cell Precursors: the

Important Targets for New Generations of Vaccines

Dr. Chunfeng Qu, Professor, Chinese Academy of Medical Sciences,

China

15:10-15:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

15:30-17:50 Track 1-3: Novel Technologies for Antigen

Discovery and Vaccine Development

Chair: Dr Louis-P. Vézina, Chief Scientific

Officer, Medicago Inc, Canada

Co-Chair: Dr. Vidadi M. Yusibov,

Executive Director, Fraunhofer USA CMB, USA

15:30-15:50 Title: VLP Express: a Discovery HT Platform

for New-generation Vaccines Based on VLPs

Dr Louis-P. Vézina, Chief Scientific Officer, Medicago Inc,

Canada

15:50-16:10 Title: Rapid Response Technology for

Vaccine Development

Dr. Vidadi M. Yusibov, Executive Director, Fraunhofer USA Center for

Molecular Biotechnology, USA

16:10-16:30 Reserved for Malvern Company(Dr. Hui

Nine)

16:30-16:50 Title: Production of FMDV Virus-like

Particles by a SUMO Fusion Protein Approach in Escherichia coli

Dr. Ting-Fang Wang, Associate Research Fellow, Institute of Molecular

Biology, Taiwan

16:50-17:10 Title: Novel Technologies for Mycoplasma

Lipid-antigen Discovery and Vaccine Development

Dr. Kazuhiro Matsuda, Associate Professor,National Institute of Advanced

Industrial Science and Technology (AIST), Japan

17:10-17:30 Title: A Role for Immunoinformatics in

Livestock T-cell Vaccines

Dr. Vish Nene, Director, International Livestock Research Institute,

Kenya

17:30-17:50 Title: Development of a Reverse Genetics

System for a Human Rrabies Virus Vaccine Strain Employed in

China

Dr. Qing Tang, Research Fellowï¼?/SPAN>National Institute for Viral

Disease Control and Prevention, China

Time and Place Co-Current Sessions and Activities

March 25, 2010 Thursday

08:10-10:10 Track 1-4: DNA Vaccine

Technologies

Chair: Dr. Bot, Vice President, Scientific

Management, MannKind Corp., USA

Co-Chair: Dr. Scherman,

Professor & Director, Laboratory of Pharmacology and Chemical

Genetics, INSERM, France

08:10-08:30 Keynote Speech:

Title: Technologies for the Discovery and Development of New

Vaccines

Dr. B. Ulmer, Global Head, External Research, Novartis Vaccines

& Diagnostics, USA

08:30-08:50 Title: Optimisation of Intradermal DNA

Electrotransfer for Immunisation

Dr. Scherman, Professor & Director, Laboratory of Pharmacology

and Chemical Genetics, INSERM, France

08:50-09:10 Title: Intra-Lymph Node DNA and Peptide

Vaccination Elicit Distinct Transcriptional Programs in CD8+T Cells, with

Implication to Vaccine

Design

Dr. Bot, Vice President, Scientific Management, MannKind Corp.,

USA

09:10-09:30 Title: Enhanced Humoral and Cell-Mediated

Immunity of Human Papillomavirus DNA Vaccine Using HERV-Expressing

Baculovirus Nanoparticles

Dr. Yu-Kyoung Oh, Associate Professor, Seoul National University, South

Korea

09:30-09:50 Title:Genetically Engineer Salmonella to

Improve DNA Vaccine Host-vector Delivery System

Dr. Wei Kong, Assistant Professor, Arizona State University, USA

09:50-10:10 Title: Efficacy of a Heptavalent CTL

Minigene Vaccine against Infection by Chlamydia Pneumoniae in Young and

Aged 57BL/6 Mice

Dr. Kerin Fresa-Dillon, Professor, Department of Pathology, Microbiology,

Immunology, Philadelphia College of Osteopathic Medicine, USA

10:10-10:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 25, 2010 Thursday

08:30-11:30 Track 1-5: Adjuvants and Vaccine Designs

(part I )

Chair: Dr. Nathalie Garcon, Vice President, Head

of Global adjuvant center for vaccines, GlaxoKline Biologicals,

Belgium

Co-Chair: Dr.Bror Morein, Professor,

Uppsala University. Sweden

08:30-08:50 Title: The GlaxoKline Adjuvant Systems

in Vaccines: Achievements and Perspectives

Dr. Nathalie Garcon, Vice President, Head of Global Adjuvant Centre for

Vaccine Development, GlaxoKline Biologicals, Belgium

08:50-09:10 Title: Applying Advances in Immunology and

Nanoparticle Technology to Develop a Novel Class of Vaccines

Dr. Grayson Lipford, Vice President of Discovery, Selecta Biosciences

Inc., USA

09:10-09:30 Title: ISCOMS, Past and Latest

Development

Dr.Bror Morein, Professor, Uppsala University. Sweden

09:30-09:50 Title: Development of in Vitro Dendritic

Cell Based Assays for the Assessment of Vaccine Adjuvants

Potential

Dr. Foti, Professor, University of Milano-Bicocca, Italy

09:50-10:10 Title:Genetically Engineer Salmonella

Containing Monophosphoryl-lipid a to Improve Vaccine Immunogenicity and

Safety

Dr. Qingke Kong, Research Fellow, Arizona State University, USA

10:10-10:30 Coffee Break

10:30-10:50 Title: Archaeal Lipid Mucosal Vaccine

Adjuvant and Delivery (AMVAD) System

Dr. Wangxue Chen, Senior Research Officer, Institute for Biological

Sciences, National Research Council Canada, Canada

10:50-11:10 Title: Vaccines against Glanders

Dr. M. Waag, Microbiologist, United States Army Medical Research

Institute of Infectious Diseases, USA

11:10-11:30 Title: Th17 Skewing Activity after

Pulmonary Delivery of Polyelectrolyte Microcapsules

Dr. Stefaan De Koker, Post-doctoral Associate, Ghent University, Belgium

Time and Place Co-Current Sessions and Activities

March 25, 2010 Thursday

10:00-12:00 Track 1-6: Innate Immunity, Mucosal

Immunity and Novel Vaccines

Chair: Dr. Kris Chadee, Professor, Department of

Microbiology and Infectious Diseases, University of Calgary,

Canada

Co-Chair: Dr. Chih-Hsiang Leng,

Associate Investigator, National Health Research Institutes,

Taiwan

10:00-10:20 Title: Mucosal immunization against

Bacterial Respiratory Infections

Dr. Allan W Cripps, Professor, Pro Vice Chancellor (Health), Griffith

University, Australia

10:20-10:40 Title: Advances in Vaccine Development for

the Parasite Entamoeba Histolytica

Dr. Kris Chadee, Professor, Department of Microbiology and Infectious

Diseases, University of Calgary, Canada

10:40-11:00 Title: Piglet Model for Assessing

Enterotoxigenic E. coli Vaccine Candidates

Dr. Francis, Professor, South Dakota State University, USA

11:00-11:20 Title: The Importance of Mucosal Immunity

in Generating Vaccines against Latent and Persistent Viral

Infections

Dr. Liljana Stevceva, Associate Professor of Immunology and Microbiology,

The School of Medicine, USA

11:20-11:40 Title: A Novel Technology for the

Production of Heterologous Lipidated Immunogens in High Yield Has

Implications for the Field of Vaccine

Design

Dr. Chih-Hsiang Leng, Associate Investigator, National Health Research

Institutes, Taiwan

11:40-12:00 Title: A Novel Recombinant Lipoprotein

Induces TLR2-mediated Gene Expression Profile is Different from Synthetic

Tri- and Di-acyl Lipopeptide

Dr. Shih-Jen Liu, Assistant Investigator, National Health Research

Institutes, Taiwan

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

16:20-17:10 Track 1-7: Cytokine Networks in Vaccine

Designs

Chair: Dr. Jeng-Jong Hwang, Professor, National

Yang-Ming University, Taiwan

Co-Chair: Dr. Jishu Shi, Founder and

CEO, Vaxiam, Associate Professor, Department of Anatomy and Physiology,

College of Veterinary Medicine, Kansas

State University, USA

16:20-16:45 Title: Evaluation of Cytokine-based

Adjuvants Using Swine Influenza Virus Antigens

Dr. Jishu Shi, Founder and CEO, Vaxiam, Associate Professor, Department

of Anatomy and Physiology, College of Veterinary Medicine, Kansas State

University,

USA

16:45-17:10 Title: DNA Vaccine in Treatment of Kidney

Diseases

Dr. Guoping Zheng, Research Fellow, Centre for Transplantation and Renal

Research, The University of Sydney, Australia

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

13:30-16:20 Track 1-8: Novel Vaccine Delivery

Technologies

Chair: Dr. Jeng-Jong Hwang, Professor, National

Yang-Ming University, Taiwan

Co-Chair: Dr. Jishu Shi, Founder and

CEO, Vaxiam, Associate Professor, Department of Anatomy and Physiology,

College of Veterinary Medicine, Kansas

State University, USA

13:30-13:55 Keynote Speaker:

Title: Difficulties and Opportunities in Producing VLP Vaccines for

Infectious Diseases and Other Disorders

Dr. M. Galarza, CEO, TechnoVax, Inc., USA

13:55-14:20 Title: Maltodextrin Nanoparticles as

Vectors Through Biological Membranes, Applications in Prophylactic and

Therapeutic Vaccine

Dr. Didier Betbeder, Professor,Physiology Laboratory, University of

Lille2 and University of Artois, France

14:20-14:45 Title: Vaccine Delivery Needs and

Challenges for Emerging Markets

Dr. Joanne Huang, Senior Scientist, Parenteral Technologies, BD

Technologies, USA

14:45-15:10 Title: Nano-engineered Capsules for

Efficient DC Targeting and T-cell Activation in Vitro and in

Vivo

Dr. Bruno De Geest, Post-doctoral Associate, Ghent University,

Belgiu

15:10-15:30 Coffee Break

15:30-15:55 Title: Therapeutic Efficacy Evaluation of

In-111-labeled PEGylated Liposomal Drug in Human and Murine Colon

Carcinomas with Multimodalities

of Molecular Imaging

Dr. Jeng-Jong Hwang, Professor, National Yang-Ming University, Taiwan

15:55-16:20 Title: A Novel Nanogel-based Delivery

System for Adjuvant-free Intranasal Vaccines

Dr. Yoshikazu Yuki, Assistant Professor, The University of Tokyo,

Japan

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

13:30-16:50 Track 1-9: Adjuvants and Vaccine

Designsï¼?/SPAN>part IIï¼?/SPAN>

Chair: Dr. Kei Amemiya, Principal Investigator,

US Army Medical Research Institute of Infectious Diseases, USA

Co-Chair: Dr. Leonard A. ,

Senior Research Scientist (ST), Medical Countermeasures Technology, Army

Medical Research and Materiel Command, USA

13:30-13:50 Title:Augmentation of the Immune Response

to the Current Bipart F1-V Plague Vaccine

Dr. Kei Amemiya, Principal Investigator, US Army Medical Research

Institute of Infectious Diseases, USA

13:50-14:10 Title: Finding a New Vaccine in a Ricin

Protein Fold

Dr. Leonard A. , Senior Research Scientist, Medical Countermeasures

Technology, Army Medical Research and Materiel Command, USA

14:10-14:30 Title: Recombinant Antigen Design for the

Generation of Particle-bound and Targeted Vaccine Therapeutics Using the

Exosome Delivery Pathway

Dr. Alain Delcayre, Senior Director of Research, BN-ImmunoTherapeutics,

Inc., USA

14:30-14:50 Title: Cationic Lipids Activate

TLR-dependent Cellular Cascades: Design of Adjuvants with Agonists and

Antagonists Properties

Dr. Jean-Marie Ruysschaert, Professor, Center of Structural Biology and

Bioinformatics, Belgium

14:50-15:10 Title: Cancer Vaccine Delivery System Using

Oligomannose Coated Liposomes

Dr. Yuzuru Ikehara, Team Leader, National Institute of Advanced

Industrial Technology (AIST), Japan

15:10-15:30 Coffee Break

15:30-15:50 Title: Improved Immunogenicity of

Adenoviral Vaccines: Impact of Tethering the Vaccine Antigen to MHC-class

II Associated Invariant Chain

Dr. Jan Pravsgaard Christensen, Associate Professor, University of

Copenhagen, Denmark

15:50-16:10 Title: Designing Novel Vaccine Adjuvants by

Targeting Mast Cells

Dr. Xiang Zou, Adjunct Professor, Nanjing Medical University,

China

16:10-16:30 Title: Immunity by Formulation Design:

Customizing the Adjuvant Properties of Cationic Liposomes by Rational

Combination with

Immunopotentiators

Dr. Camilla Foged, Associate Professor, University of Copenhagen,

Denmark

16:30-16:50 Title: Probiotics can Improve Response to

Vaccination

Dr. Bourbié-Vaudaine, Research Scientist, Danone Research,

France

Track 2: Human Vaccines:-Major Infectious Diseases

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

13:30-15:10 Track 2-1: Hepatitis Vaccines

Chair: Dr. Frederic J. Deschamps, Professor,

Department Occupational Health, France

Co-Chair: Dr. Kow-Tong Chen,

Professor & Chairman, Department of Public Health, College of

Medicine, National Cheng Kung University, Taiwan

13:30-13:55 Title: Assessment of Protective

Immunization of Workers Exposed to Hepatitis B Contamination

Dr. Frederic J. Deschamps, Professor, Department Occupational Health,

France

13:55-14:20 Title: Hepatitis B and Hepatitis A Virus

among Drug Users. The Rolf of Vaccination

Dr. Fabio Lugoboni, Director, Universitary Hospital, Italy

14:20-14:45 Title:Preoperative vaccination for HBV in

Polish Hospitals as a Possible Public Health Tool to Limit the Spread of

an Epidemic

Dr. Ganczak, Assistant Professor, Faculty of Medical Sciences,

Pomeranian Medical University, Poland

14:45-15:10 Title: HBV Prophylaxis after Liver

Transplantation by Active Vaccination

Dr. Mikiko Ueda, Associated Director, sakafu-Saiseikai-Noe-Hospital,

Japan

15:10-15:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

15:30-16:20 Track 2-2: Herpes Virus and Measles

Vaccines

Chair: Dr. Frederic J. Deschamps, Professor,

Department Occupational Health, France

Co-Chair: Dr. Kow-Tong Chen,

Professor & Chairman, Department of Public Health, College of

Medicine, National Cheng Kung University, Taiwan

15:30-15:55 Title: Epidemiologic Features of Measles in

Taiwan, 1999-2008

Dr. Kow-Tong Chen, Professor & Chairman, Department of Public Health,

College of Medicine, National Cheng Kung University, Taiwan

15:55-16:20 Title: TBD

Dr. Honghai Wang, Professor, Fudan University, China

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

08:30-09:20 Track 2-3: Gastrointestinal Infection

Vaccines

Chair: Dr. Roy Curtiss III, Professor of Life

Sciences, School of Life Sciences Director, Center for Infectious

Diseases and Vaccinology, The Biodesign

Institute, Arizona State University, USA

Co-Chair: Dr. Malabi M. Venkatesan,

Task AD Group Leader, Walter Army Institute of Research,

USA

08:30-08:55 Title: Live Oral Shigella Vaccines, That

Lack VirG(icsA), SenA(shET2-1), SenB(shET2-2) and MsbB2 Genes are

Predicted to be Safer but Equally

Immunogenic and Efficacious as Previously Tested Vaccine Candidates That

Lack Principally the VirG(icsA) Gene

Dr. Malabi M. Venkatesan, Task AD Group Leader, Walter Army

Institute of Research, USA

08:55-09:20 Title: Antitoxin Vaccine Development

against Enterotoxigenic Escherichia coli (ETEC) Associated

Diarrhea

Dr. Weiping Zhang, Assistant Professor, South Dakota State University,

USA

09:20-09:40 Coffee Break

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

09:40-12:10 Track 2-4: HPV Vaccine to Gynecological

Vaccines

Chair: Dr. Jovelle B. Laoag-Fernandez, Director,

Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoKline

Biologicals, Belgium

Co-Chair: Dr. Cecilia A.

Ladines-Llave, Professor and Chair, Cancer Institute, Million to the

University of the Philippines Manila-Philippine General

Hospital, Philippines

09:40-10:05 Title: HPV-16/18 AS04-adjuvanted Vaccine,

the Benefits to Girls and Women: From Clinical Trials to Clinical

Practice

Dr. Jovelle B. Laoag-Fernandez, Director, Global Medical Affairs,

Adolescent and Adult Vaccines, GlaxoKline Biologicals,

Belgium

10:05-10:30 Title: The Cecap Framework: Linking

Vaccination to Screening Platform in Developing Countries

Dr. Cecilia A. Ladines-Llave, Professor and Chair, Cancer Institute,

Million to the University of the Philippines Manila-Philippine General

Hospital,

Philippines

10:30-10:55 Title: Insight into the Immunological

Potential of Adjuvanted HPV Vaccines

Dr. Graeme N V Hacking, Director, Clinical R & D and Medical Affairs

GlaxoKline Biologicals, Belgium

10:55-11:20 Title: Update on Gardasil (Quadrivalent

Human Papillomavirus [hpv] 6/11/16/18 Vaccine) Clinical Trial Efficacy

Results

Dr. Randall N. Hyer, Senior Director, Banyu Pharmaceutical Co., LTD,

Japan

11:20-11:45 Title: Trivalent Human Papillomavirus (HPV)

VLP Vaccine Covering HPV Type 58 can Elicit High Level of Humoral

Immunity but also Induce

Interferences among Component Types

Dr. Xuemei Xu, Professor of Institute of Basic Medical Sciences, Chinese

Academy of Medical Sciences, School of Basic Medicine Peking Union

Medical College,

China

11:45-12:10 Title: Implementation of Cervical Cancer

Vaccination: Current Success and Future Challenges

Dr. Taek Sang Lee, Assistant professor, Committee Member of KGOG,

Republic of Korea

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

14:40-17:15 Track 2-5: Flaviviruses

Vaccines-Caliciviruses, Dengue and Japanese Encephalitis

Chair: Dr. Liljana Stevceva, Associate Professor

of Immunology and Microbiology, The School of Medicine,

USA

Co-Chair: Dr. Chaoping Chen,

Assistant Professor, Colorado State University, USA

14:40-15:05 Title: The Chimerivax Platform for Dengue

and JE Vaccines

Dr. Almond, Vice President, Global Research and External Research

and Development, Sanofi-Pasteur, France

15:05-15:30 Title: Host-range Mutations-a Novel Method

for Developing Vaccines against Arthropod-borne Viral Diseases

Dr. Malcolm , President and CEO, Arbovax, Inc, USA

15:30-15:55 Title: Intracellular Expression of Aptamers

Targeting Flavivirus NS5 Capping Enzyme as Novel Vaccines

Dr. Chaoping Chen, Assistant Professor, Colorado State University,

USA

15:55-16:20 Title: Development of Cell Culture-derived

Japanese Encephalitis Vaccine (Inactivated)

Dr. Yuko Muraki, Research Scientist, The Research Foundation for

Microbial Diseases of Osaka University, Japan

16:20-16:25 Title: Flaviviruses Vaccines

Dr. Musaad Ahmad Aldubaib, Chairman, Qassim University, Saudi

Arabia

16:25-16:50 Title: Dengue Virus Host Factors

Dr. October Sessions, Research Fellow, Duke-NUS, Singapore

16:50-17:15 Title:The Burden of Dengue Infection in

Hyperendemic Area, Indonesian Perspective: the Urgent Need of

Vaccine

Dr. Leonard Nainggolan, Internist, Faculty of Medicine University of

Indonesia, Indonesia

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

13:30-14:20 Track 2-6: Diarrhoeal Disease

Vaccines-Enterotoxigenic Escherichia coli, Rotavirus, Shigellosis and

Typhoid

Chair: Dr. O. Favorov, Deputy

Director-General, Director of Translational Research Division,

International Vaccine Institute, Korea

Co-Chair: Dr. Chaoping Chen,

Assistant Professor, Colorado State University, USA

13:30-13:55 Title: Can Typhoid be Eliminated?

Dr. O. Favorov, Deputy Director-General, Director of

Translational Research Division, International Vaccine Institute,

Korea

13:55-14:20 Title: Rotavirus Vaccine Trials in

Bangladesh: Experience in Phase I to IV Studies

Dr. K. Zaman, Scientist & Epidemiologist, International Centre for

Diarrhoeal Disease Research, Bangladesh (ICDDR,

14:20-14:40 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

08:30-11:30 Track 2-7: Influenza Vaccines

Chair: Dr. M. Galarza, CEO & President,

TechnoVax, Inc., USA

Co-Chair: Dr. Xuguang () Li,

Professor, Department of Biochemistry, Microbiology & Immunology,

Faculty of Medicine, University of Ottawa, Canada

08:30-08:50 Keynote Speech:

Title: Progress in Pandemic Vaccine Development and Manufacturing

Dr. Oleg I. Kiselev, Academician, Russian Academy of Medical Sciences,

Russia

08:50-09:10 Title: Monovalent and Polyvalent Influenza

Virus-Like Particles as Effective and Economical Human and Animal

Vaccines

Dr. M. Galarza, CEO, TechnoVax, Inc., USA

09:10-09:30 Title:VLP Vaccines in Response to Influenza

Pandemic: Preclinical and Clinical Evaluation of a Plant-made VLP Vaccine

for H5N1 Strains

Dr. Nathalie Landry, Vice President, Product Development, Medicago Inc,

Canada

09:30-09:50 Title: Targeting the most Conserved

Sequences of Virtually all Subtypes of the Influenza A Viral

Hemagglutinins

Dr. Xuguang () Li, Professor, Department of Biochemistry,

Microbiology & Immunology, Faculty of Medicine, University of Ottawa,

Canada

09:50-10:10 Title: Rational Design of Pandemic

Influenza Vaccines

Dr. Honglin Xu, Director, Laboratory of Virology, National Vaccine and

Serum Institute, China

10:10-10:30 Coffee Break

10:30-10:50 Title: Understanding Immune Protection

Mechanisms of an Influnza a Virus M2 Peptide Vaccine

Dr. W. Washabaugh, Senior Director, Merck Research Laboratories,

Merck & Co., Inc., USA

10:50-11:10 Title: A Novel Assay for Influenza Virus

Quantification Using Surface Plasmon Resonance

Dr. Raf Lemmens, Global Fast Trak Leader, GE Healthcare Life Sciences,

Sweden

11:10-11:30 Title:Attenuated Bordetella Pertussis

Protects against Influenza A Lethal Challenge by Dampening the Cytokine

Storm

Dr Alonso Sylvie, Assistant Professor, Department of Microbiology,

Immunology Programme, National University of Singapore,

Singapore

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

11:30-12:10 Track 2-8: Vaccines on Avian Flu

Chair: Dr. M. Galarza, CEO & President,

TechnoVax, Inc., USA

Co-Chair: Dr. Xuguang () Li,

Professor, Department of Biochemistry, Microbiology & Immunology,

Faculty of Medicine, University of Ottawa, Canada

11:30-11:50 Title: Development of Baculovirus as a New

Avian Influenza Vaccine Platform

Dr. Yu-Chen Hu, Professor, National Tsing Hua University, Taiwan

11:50-12:10 Title: Proposal and Method of Artificial

Influenza Pandemic by Live Attenuated Infectious Vaccine to Prevent

Natural Pandemic H5N1

Dr. Yoshinori Hayakawa, Professor, Toin University of Yokohama, Japan

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

15:30-16:10 Track 2-9: Vaccines on Swine Flu

Chair: Dr. Miles Carroll, Head, Health Protection

Agency, Uk

Co-Chair: Dr. Jinling Li, Research

Scientist, Medicine & Epidemiology, School of Veterinary Medicine,

University of California, , USA

15:30-15:50 Title: Development and Application of

Animal Models for the Evaluation of Swine Flu Vaccines.

Dr. Miles Carroll, Head, Health Protection Agency, U.K

15:50-16:10 Title: Genetic Alterations of Hemagglutinin

Associated with Species-specific Neuraminidase Stalk Deletions and the

Implication in Vaccine

Development

Dr. Jinling Li, Research Scientist, Medicine & Epidemiology, School

of Veterinary Medicine, University of California, USA

16:10-16:20 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

15:30-17:30 Track 2-10: Pneumococcus and Respiratory

Syncytial Virus

Chair: Dr. Jennelle Kyd, Professor & Deputy

Vice-Chancellor, Central Queensland University, Australia

Co-Chair: Dr. Kerin Fresa-Dillon,

Professor,Department of Pathology, Microbiology,

Immunologyï¼?/SPAN>Philadelphia College of Osteopathic Medicine,

USA

15:30-15:50 Keynote Speech:

Title: A Live Recombinant Attenuated Salmonella Anti-Pneumococcal Vaccine

for Newborns

Dr. Roy Curtiss III, Academician, United States National Academy of

Sciences, USA

15:50-16:10 Keynote Speech:

Title:Development of a Full Coverage Pneumococcal Vaccine Comprising

Highly Conserved Proteins: from Discovery to the First Clinical Trial

Dr. Eszter Nagy, Senior Vice President, Pre-clinical Research &

Development, Intercell AG, Austria

16:10-16:30 Title: Bacterial Interactions Associated

with Pneumococcal Respiratory Infections: Challenge to Vaccine

Strategies

Dr. Jennelle Kyd, Professor & Deputy Vice-Chancellor, Central

Queensland University, Australia

16:30-16:50 Title: A New, Single Protein as a Vaccine

with Broad Effects for Prevention of Pneumococcal Infections

Dr. Dong-Sheng Chen, President/CEO, Synergy America, Inc., USA

16:50-17:10 Title: Using New Pneumococcal Vaccines in

Combination for Maximum Protection

Dr. J Leach, Associate Professor, Child Health Division, Menzies

School of Health Research Australia

17:10-17:30 Title: Pneumococcal Conjugate Vaccine-7:

Effect on Serotypes/Groups and Antimicrobial Susceptibility of

Streptococcus Pneumonia in Kuwait

Dr. Eiman Mokaddas, Professor of Clinical Microbiology, Chairman

Microbiology Department, Kuwait University, Kuwait

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

13:30-16:45 Track 2-11: Malaria and Tuberculosis

Vaccines

Chair: Dr. Yasir A.W. Skeiky,CSO, Aeras Global TB

Vaccine Foundation, USA

Co-Chair: Dr. Zhongming Li,

President/CEO, Shanghai H & G Biotechnology Inc., China

13:30-13:55 Title: Development of a Live Vaccine

(rBCGΔureC::Hly/VPM1002) against Tuberculosis

Dr. Bernd Eisele, CEO of VPM Inc., Germany

13:55-14:20 Title: Prime-boost Vaccination in the

Control of Tuberculosis

Dr. Yasir A.W. Skeiky,Chief Scientific Officer, Aeras Global TB Vaccine

Foundation, USA

14:20-14:45 Title: Development of MVA85A, a Leading

Tuberculosis Vaccine Candidate

Dr. Shea, General Manager, Oxford-Emergent Tuberculosis

Consortium Ltd, UK

14:45-15:10 Title: Immunotherapy of

Multi-drug-resistant (MDR) Mycobacterium Tuberculosis Infected Mice Using

DNA Vaccines or in Combination with

Chemotherapy

Dr. Zhongming Li, President/CEO, Shanghai H & G Biotechnology Inc.,

China

15:10-15:30 Coffee Break

15:30-15:55 Title: Subunit Vaccine Combining Multiple

Antigens Improves BCG-primed Protective Efficacy against Mycobacterium

Tuberculosis Infection in

Mice

Dr. Bingdong Zhu, Vice Professor, Lanzhou University, China

15:55-16:20 Title: A Recombinant BCG Expressing the

Fusion Protein PE_MPT64 Induces Enhanced Activity against Mycobacterium

Tuberculosis in Mice

Dr. Giovanni Delogu, Professor, Catholic University, Italy

16:20-16:45 Title: Prospects for Post-infection

Vaccines and Adding Adjunctive Immunotherapy to Anti-Tuberculosis

Chemotherapy

Dr. B Lowrie (Daoliang Luo), Senior Research Fellow, Fudan

University, China

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

13:30-15:10 Track 2-12: Parasitic Disease

Vaccines-Hookworm, Leishmaniasis, Schistosomiasis

Chair: Dr. Hira L. Nakhasi, Director, Division of

Emerging and Transfusion Transmitted Diseases, OBRR/CBER/FDA,

USA

Co-Chair: Dr. Don McManus, Head,

Molecular Parasitilogy Unit, Queensland Institute of Medical Research,

Australia

13:30-13:50 Keynote Speech:

Title: Can the Current Approach Effectively Conquer Schistosomiasis?

Dr. Bergquist, Editor-in-Chief of Geospatial Health,

Sweden

13:50-14:10 Title: Live Attenuated (Genetically

Modified) Leishmania Vaccines: Evaluation of Safety and Immunogenicity

Dr. Hira Nakhasi, Director, Division of Emerging and Transfusion

Transmitted Diseases, US Food and Drug Administration, USA

14:10-14:30 Title: Mucosal Vaccines for Systemic

Leishmaniasis

Dr. Bartira Rossi-Bergmann, Professor, Institute of Biophysics, Federal

University of Rio de Janeiro, Brazil

14:30-14:50 Title: Prospects for Development of a

Transmission Blocking Vaccine against Schistosoma Japonicum

Dr. McManus, Head, Molecular Parasitology Laboratory, Queensland

Institute of Medical Research, Australia

14:50-15:10 Title: Development of a Bivalent Anti

Helminth Vaccine against Schistosomiasis and Fascioliasis

Dr. Miriam Tendler, Full Researcher, Oswaldo Cruz Foundation,

Brazi

15:10-15:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

16:20-17:40 Track 2-13: Other Infectious

Diseases

-Bacteria: Buruli Ulcer, Leptospirosis, Neisseria Meningitidis,

Streptococcus Group A/B, Trachoma

-Emerging Virus: Rubella, West Nile Fever, SARS, Ebla Virus, Prion

Toxins

Chair: Dr. Lockhart, Senior Vice

President, Product Development, Emergent BioSolutions, UK

Co-Chair: Dr. Xuming Zhang,

Professor, Department of Microbiology and Immunology, University of

Arkansas for Medical Sciences, USA

16:20-16:40 Title: Development of the MVAtorâ„?Viral

Vector Platform

Dr. Lockhart, Senior Vice President, Product Development,

Emergent BioSolutions, UK

16:40-17:00 Title: An Update on the Development of SARS

Vaccines

Dr. Xuming Zhang, Professor, Department of Microbiology and Immunology,

University of Arkansas for Medical Sciences, USA

17:00-17:20 Title: Advances in Vaccines against Group B

Meningococci

Dr. Xilian Bai, Head, Health Protection Agency Vaccine Evaluation Unit,

UK

17:20-17:40 Title: Innate Immune Recognition of

Neisseria Meningitidis Capsular Polysaccharides

Dr. Susu Zughaier,Research Assistant Professor, Division of Infectious

Diseases,Emory University School of Medicine, USA

Track 3: Human Vaccines: AIDS Vaccines

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

11:30-12:10 Track 3-1: Epidemiology, Prevention

Research, and Economic Sciences

Chair: Dr. Bot, Vice President, Scientific

Management, MannKind Corp., USA

Co-Chair: Dr. Scherman,

Professor & Director, Laboratory of Pharmacology and Chemical

Genetics, INSERM, France

11:30-11:50 Title: Eradication of Helminth Infections

in Developing Countries is Essential for Successful Vaccination

Dr. Zvi Bentwich, Professor, Ben Gurion University of the Negev,

Israel

11:50-12:10 Title: Advocacy Strategies for Recruitment

of Volunteers for Phase I HIV Vaccine Trials in Chennai, India

Dr. V. D. Ramanathan, Scientist F, Department of Clinical Pathology,

Tuberculosis Research Centre, India

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

08:30-09:45 Track 3-2: Innate Immunity, Dendritic

Cells, and T Cell Immunity

Chair: Dr. Xia Jin, Associate Professor,

University of Rochester School of Medicine and Dentistry, USA

Co-Chair: Dr. Dinesh K. Singh,

Associate Professor, Norfolk State University, USA

08:30-08:55 Title: Mimics of B-cell Epitopes for

Designing of HIV-1 Vaccine Candidates

Dr. A.Ilyichev, Professor, State Research Center of Virology

and Biotechnology Vector, Russia

08:55-09:20 Title: A Novel HIV T Helper Epitope-based

Vaccine Elicits Poly-functional HIV-specific CD4+ T Cells in a Phase I

Clinical Trial in HIV-uninfected Adults

Dr. Xia Jin, Associate Professor, University of Rochester School of

Medicine and Dentistry, USA

09:20-09:45 Title: Trafficking of HIV-1 in Human

Dendritic Cells

Dr. Dinesh K. Singh, Associate Professor, Norfolk State University,

USA

09:45-10:00 Coffee Break

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

15:00-16:00 Track 3-3: Neutralizing Antibodies and

Immune Escape

Chair: Dr. Moyle, Chief Scientific

Officer, Theraclone Sciences, Inc, USA

Co-Chair: Dr. Catarina E. Hioe,

Associate Professor of Pathology, New York University, USA

15:00-15:20 Title: Human Antibodies Identify Highly

Conserved Functional Epitopes on HIV-1 and Influenza Viruses

Dr. Moyle, Chief Scientific Officer, Theraclone Sciences, Inc,

USA

15:20-15:40 Title: GBV-C Envelope Glycoprotein 2 (E2)

Elicits Antibodies Neutralize HIV Infectivity in Vitro --a Novel HIV

Vaccine Candidate?

Dr. Jinhua Xiang, Associate Research Scientist, The University of Iowa

& Iowa City VAMC Research, USA

15:40-16:00 Title: Transmitted HIV-1 Variants in HIV

Infected Mother-child pairs, Carrying Different Subtypes

Dr. Anneka Ehrnst, Adjunct Professor, Karolinska Institutet, Sweden

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

13:30-14:50 Track 3-4: Validation of Animal Models and

Clinical Trials on AIDS Vaccines

Chair: Dr. Harriet L. ,Chief Scientific

Officer, GeoVax Inc., USA

Co-Chair: Dr. Shixia Wang, Associate

Professor, University of Massachusetts Medical School, USA

13:30-13:50 Title: Phase 1 Safety and Immunogenicity

Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines

Expressing HIV-1 Virus-Like

Particles

Dr. Harriet L. , Chief Scientific Officer, GeoVax Inc.,

USA

13:50-14:10 Title: Heterologous Prime-Boost HIV Vaccine

in Preclinical Animal Studies

Dr. Shixia Wang, Associate Professor of Medicine, Laboratory of Nucleic

Acid Vaccines, Department of Medicine, University of Massachusetts

Medical School,

USA

14:10-14:30 Title: Phase 1 Preclinical Studies on

DNA/MVA Vaccines, Co-expressed GM-CSF, a Strong Adjuvant for Prevention

of Acquisition

Dr. Lilin Lai, Research Associate, Emory University, USA

14:30-14:50 Title: A Framework for Assessing

Immunological Correlates of Protection in Vaccine Trials

Dr. Li Qin, Assistant Member, Fred Hutchinson Cancer Research Center,

USA

14:50-15:00 Coffee Break

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

16:00-17:20 Track 3-5: Novel AIDS Vectors and

Immunogen

Chair: Dr. Moyle, Chief Scientific

Officer, Theraclone Sciences, Inc, USA

Co-Chair: Dr. Catarina E. Hioe,

Associate Professor of Pathology, New York University, USA

16:00-16:20 Title: Polyepitope Based Approach for

Developing Artificial T- and B-Cell Immunogens as HIV-1 Vaccine

Dr. Larisa I. Karpenko, Head, State Research Center of Virology and

Biotechnology Vector, Russia

16:20-16:40 Title:Use of Immune Complexes too Enhance

Antibody Responses to HIV-1 Neutralizing Epitopes

Dr. Catarina E. Hioe, Associate Professor, NYU School of Medicine,

USA

16:40-17:00 Title: Structure-based Design of Immunogens

Aiming at the V3 Epitope of HIV-1 gp120

Dr. Xiangpeng Kong, Associate Professor, Biochemistry Department, USA

17:00-17:20 Title: Lentiviral DNA as Vaccine

Candidates

Dr. Dinesh K. Singh, Associate Professor, Norfolk State University,

USA

Track 4: Human Vaccines: Non-Infectious Diseases

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

10:30-12:10 Track 4Human Vaccines: Non-Infectious

Diseases

�CNS Vaccines

�Autoimmune Diseases and Type 1 Diabetes Vaccines

�Cardiovascular Diseases

�VaccinesAddiction Vaccines

�Challenges on Therapeutic Vaccines and Clinical Development

Chair: Dr. Jaroslav Michálek, Professor, Masaryk

University, Czech Republic

Co-Chair: Dr. Gottlieb,

Associate Professor, Barbara Center, University of Colorado at

Denver School of Medicine, USA

10:30-10:50 Title:Optimized Maturation Coctail for

Clinical Grade Dendritic Cell Vaccination

Dr. Jaroslav Michálek, Professor, Masaryk University, Czech Republic

10:50-11:10 Title: Development and Validation of Assays

for Vaccine Stability and Batch Release

Dr. Bassam Hallis, General Project Manager, Centre for Emergency

Preparedness and Response, Health Protection Agency, UK

11:10-11:30 Title: Interim Results of a Phase I/II

Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1

Diabetes

Dr. Gottlieb, Associate Professor, Barbara Center, University

of Colorado at Denver School of Medicine, USA

11:30-11:50 Title: A Novel T-cell Independent Liposomal

Amyloid-beta Vaccine for the treatment of Alzheimer's Disease

Dr. Alberto Silva, Research Scientist, ,Biology-AC Immune SA,

Switzerland

11:50-12:10 Title: Effect of Oral Vaccination with

Pooled Antigens Derived from Adipose Tissue on Atherosclerosis and

Obesity Indices

Dr. Aldar S. Bourinbaiar,CEO, Immunitor USA Inc., USA

Track 5: Human Vaccines: Cancer Vaccines

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

08:30-10:35 Track 5-1: Cancer Epidemiology, Tumor

Immunology, and Immunotherapy

Chair: Dr. Giulio Tarro, Professor, Division of

Infectious Diseases, D Cotugno Hospital, Italy

Co-Chair: Dr. Heng Zhao, Professor,

Chinese Academy of Agricultural Sciences, China

08:30-08:55 Title: A Prophylactic Vaccine against

Cervical Cancer and Genital Warts - Gardasil® : Key Comparability

Analyses for Quadrivalent Human

Papilloma Virus (HPV, types 6, 11, 16 and 18) L1 Based Virus-like

Particles

Dr. Qinjian Zhao, Distinguished Senior Investigator, Bioprocess

Analytical and Formulation Sciences, Merck Research Laboratories, Merck

& Co., Inc, USA

08:55-09:20 Title: Tumor Liberated Protein from Cancer

and Perspectives for Immunotherapy

Dr. Giulio Tarro, Professor,Division of Infectious Diseases, D Cotugno

Hospital, Italy

09:20-09:45 Title: Linking Evidence-based Vaccinology

and Economic Analysis in a CPG for Vaccines in Cancer Patients

Dr. Liliana Chicaiza, Associate Professor, National University of

Colombia, USA

09:45-10:10 Title: Recombinant Newcastle Disease Virus

as a Potential Candidate for CancerTherapy

Dr. Heng Zhao, Professor, Chinese Academy of Agricultural Sciences,

China

10:10-10:35 Title: There is More to the Solute r

Family 11 Member 1(SLC11A1) than Cytokine Regulation.

Dr. Agnes Abiola Awomoyi, Scientist, Internal Medicine Ohio State

University, USA

10:35-10:45 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

10:35-11:15 Track 5-2: New Cancer Vaccine Discovery

Technologies for Targetable Antigens

Chair: Dr. Jagat Kanwar, Associate Professor,

Institute for Technology Research and Innovation (ITRI), Deakin

University, Australia

Co-Chair: Dr. Heng Zhao, Professor,

Chinese Academy of Agricultural Sciences, China

10:35-10:50 Title: Biotechnology Beyond Boundaries,

Nanocarriers Delivery of Small Interfering RNA and micro RNA: Promises of

Cancer Gene Therapy

Dr. Jagat Kanwar, Associate Professor, Institute for Technology Research

and Innovation (ITRI), Deakin University, Australia.

10:50-11:15 Title: Adenoviral Vaccination against

Cancer

Dr. Rathmann Sørensen, Postdoc,University of Copenhagen, Denmark

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

13:30-15:10 Track 5-3: Dendritic Cell based Cancer

Vaccines

Chair: Dr. Barbara Guinn, Senior Research Fellow,

Cancer Sciences Division (MP824), University of Southampton, UK

Co-Chair: Dr.Jochen Greiner,

Professor, University of Ulm,Germany

13:30-13:50 Title: Dendritic Cell Targeting to Enhance

CD4 and CD8 T Cell Immunity against Cancer

Dr. Yvette van Kooyk, Professor, Department of Molecular Cell Biology and

Immunology, VU University Medical Center, The Netherlands

13:50-14:10 Title: A Clinical Trial of Interleukin-13

Receptor Alpha 2 Peptide-pulsed DC Vaccine for Malignant

Gliomas

Dr. Atsushi Natsume, Associate Professor, Nagoya University,

Japan

14:10-14:30 Title: Dendritic Cell Vaccination to

Improve Adoptive T-cell Transfer in Metastatic Melanoma

Dr. Lizee, Assistant Professor, University of Texas M.D.

Cancer Center, USA

14:30-14:50 Title: Effective Cancer Vaccination by

Adenovirus Gene Therapy Vector and Integrin Expressing Dendritic Cells

(DC)

Dr. Saroj K. Basak, Assistant Researcher, University of California Los

Angeles, USA

14:50-15:10 Title:Controllable Live Dendritic Cell

Vaccine Induce Antitumor Immunity against Ovarian Cancer

Dr. Yu Kang,Research Fellow, Fudan University, China

15:10-15:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

13:30-15:30 Track 5-4: Adjuvants for the Development of

Cancer Vaccines

Chair: Call for Host

Co-Chair: Call for Co-Host

13:30-13:55 Speech Opportunity Available

13:55-14:20 Title: Immunpotentiators in Modern

Vaccines

Dr. Virgil Schijns, Professor, Immune Intervention, Wageningen

University; Vice president of R & D, Crossbeta Biosciences B.V., The

Netherlands

14:20-14:45 Speech Opportunity Available

14:45-15:10 Title: CD4 Help in Cancer Vaccine

Dr. Yassine Taoufik, Faculty, University of Paris, France

15:10-15:30 Coffee Break

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

15:30-16:20 Track 5-4: Vaccine Approaches to

Immunotherapy and Clinical Trials

Chair: Dr. Barbara Guinn, Senior Research Fellow,

Cancer Sciences Division (MP824), University of Southampton, UK

Co-Chair: Dr.Jochen Greiner,

Professor, University of Ulm,Germany

15:30-15:50 Keynote Speech:

Title: Transgene’s Therapeutic Vaccines

Dr. Jean-Yves Bonnefoy, Vice-President, Transgene S.A., France

15:50-16:10 Title: A New DNA Vaccines for Acute Myeloid

Leukemia

Dr. Barbara Guinn, Senior Research Fellow, Cancer Sciences Division

(MP824), University of Southampton, UK

16:10-16:30 Title: WT1-targeted Dendritic Cell

Vaccination as Post-remission Immunotherapy of Acute Myeloid Leukemia

Dr. Viggo Van Tendeloo, Associate Professor, Vaccine & Infectious

Disease Institute, Center for Cellular Therapy & Regenerative

Medicine, Antwerp University

Hospital, Belgium

16:30-16:50 Title: Preclinical Studies of Carbohydrate

Mimetic Peptide Vaccines for Breast Cancer and Melanoma

Dr. Kieber-Emmons, Professor & Deputy Director, University of

Arkansas for Medical Sciences, USA

16:50-17:10 Title: Leukemia-associated Antigens as

Target for Vaccination Strategies in AML

Dr. Jochen Greiner, Professor, University of Ulm, Germany

17:10-17:30 Title: Newcastle Disease Virus: a Promising

Delivering System for Cancer Immunotherapy

Dr. Haiyan Liu, Professor, Soochow University, China

Track 6: Public Health, Economics, Safety/Ethic and Regulatory

Aspects

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

13:30-16:20 Track 6-1: Safety Evaluation of

Vaccines

Chair: Dr. J. Malinoski, President, TD

Consultancy, LLC, USA

Co-Chair: Dr. Wisher, Senior

Scientific Director, BioReliance, UK

13:30-13:55 Title: Vaccine Safety: Pre and Post

Licensure Risk Evaluation Management Systems (REMS)

Dr. J. Malinoski,President, TD Consultancy, LLC, USA

13:55-14:20 Title: LC/MS Characterization of

Recombinant Protein Vaccine

Dr. Mazzeo, Biopharmaceutical Business Director, Pharmaceutical

Market Development, Waters Corporation, USA

14:20-14:45 Title: Vaccination: Is It a Real Problem

for Anesthesia and Surgery?

Dr. Currie, Consultant in Paediatric Anaesthesia and Pain

Management, Royal Hospital for Sick Children, UK

14:45-15:10 Title: Call Centre Informatics, Focus on

Achieving Safe and Efficacious Use of Vaccines

Dr. Halasi, Drug Information Pharmacist, Ontario Pharmacists'

Association, Canada

15:10-15:30 Coffee Break

15:30-15:55 Title: Injection Techniques to Reduce Pain

during Vaccination in Childhood

Dr. Moshe Ipp, Professor of Paediatrics, University of Toronto,

Canada

15:55-16:20 Title: Immunization Administration: Are Our

Vaccines Safe and Effective?

Dr. Pam Strohfus, Associate Professor, Boise State University,

USA

Time and Place Co-Current Sessions and Activities

March 24, 2010

Wednesday

16:20-17:10 Track 6-2: Regulatory Issues, Standards and

Quality Control over Vaccines

Chair: Dr. J. Malinoski, President, TD

Consultancy, LLC, USA

Co-Chair: Dr. Wisher, Senior

Scientific Director, BioReliance, UK

16:20-16:45 Title: Economic Analysis of Vaccines in

Immuno-compromised Patients in Middle income Countries

Dr. -Molina, Associate Professor, National University of

Colombia, USA

16:45-17:10 Title: Neglected Ethical and Regulatory

Aspects and Expectations of Vaccine Development Research

Dr. ph Mfutso-Bengo, Professor, University of Malawi, Malawi

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

16:00-17:20 Track 6-3: Public Health and New Vaccines

Developed in Asia and other Developing Countries

Chair: Dr. Jovelle B. Laoag-Fernandez, Director,

Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoKline

Biologicals, Belgium

Co-Chair: Dr. Sheng Li, Chief,

Biomedical Advanced Research & Development Authority, US Department

of Health and Human Services, USA

16:00-16:20 Title:The Time Trade off approach to

Measure Patients�Preferences for Health States Associated with

HPV-related Pathologies: a Multicenter

Study Performed in Italy

Dr. Francesco Saverio Mennini, Professor, University of Rome La Sapienza,

Italy

16:20-16:40 Title: Increasing Global Access to

Vaccinology Know-How and Technology

Dr. Jan Hendriks, Account Manager, Netherlands Vaccine Institute, The

Netherlands

16:40-17:00 Title: Immune Response to Aerosolized MMR

Vaccine in Adults

Dr. - Ortega, Medical Investigator, National Institute of

Public Health, Mexico

17:00-17:20 Title: Activities of Public Health in

Preparations for Pandemic Influence

Dr. Nada Milic, Senior Advisor, Center for Prevention and Control Disease

Institute of Public Health of Serbia, Serbia

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

13:30-14:30 Track 6-4: Vaccines against

Bioterrorism

Chair: Dr. Carol Sabourin, Chief Scientist of

Battelle Science and Technology & Senior Research Leader of National

Security Global Business, Battelle

Memorial Institute , USA

Co-Chair: Dr. Lanling Zou,

Bacteriology Program Officer & Chief Translational Sciences Section,

BMB/DMID/NIAID/NIH/DHHS, USA

13:30-13:50 Title: Animal Models to Evaluate the

Efficacy of Vaccines under the Animal Rule

Dr. Carol Sabourin, Chief Scientist of Battelle Science and Technology

& Senior Research Leader of National Security Global Business,

Battelle Memorial

Institute , USA

13:50-14:10 Title: Biodefense Effort at NIAID

Dr. Lanling Zou, Bacteriology Program Officer & Chief Translational

Sciences Section, BMB/DMID/NIAID/NIH/DHHS, USA

14:10-14:30 Title: BALB/c Mouse Antibody Responses to

Ricin Toxin

Dr. W. Cherwonogrodzky, Scientist, Defence Research and Development

Canada �Suffield, Canada

14:30-14:40 Coffee Break

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

14:40-16:00 Track 6-5: Milestone Review on Global

Vaccination Projects

Chair: Dr. Jovelle B. Laoag-Fernandez, Director,

Global Medical Affairs, Adolescent and Adult Vaccines, GlaxoKline

Biologicals, Belgium

Co-Chair: Dr. Sheng Li, Chief,

Biomedical Advanced Research & Development Authority, US Department

of Health and Human Services, USA

14:40-15:00 Title:Lessons Learned on Models of Delivery

for HPV Vaccines in Developing Countries: Initial Experiences from the

GARDASIL® Access Program

Dr. ph Saba, CEO, AXIO, France

15:00-15:20 Title: New Perspectives for Vaccine

Development: the Value of Adjuvantation

Dr. Graeme N V Hacking, Director, Clinical R & D and Medical Affairs,

Vaccines �Emerging Markets, GlaxoKline, Belgium

15:20-15:40 Title: Funding New Technologies for the

Development of Seasonal and Pandemic Influenza Vaccines

Dr. Sheng Li, Chief, Biomedical Advanced Research & Development

Authority, US Department of Health and Human Services, USA

15:40-16:00 Title: 30 Years Experience in the Use of

Aerosol Route for Viral Vaccines

Dr. Fernández de Castro P., External Consultant, Felipe Ochoa y

Asociados, S.C., Mexico

Track 7: Livestock/Veterinary/ Aquaculture Vaccine R & D

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

08:30-11:10 Track 7-1: Veterinary Immunity and Vaccine

Development

Chair: Dr. Potter, CEO and Director,

Vaccine and Infectious Disease Organization, Canada

Co-Chair: Dr. McVey,

Professor & Director, University of Nebraska, USA

08:30-08:50 Title: Development of Vaccines for the

Control of Foodborne Zoonotic Pathogens

Dr. Potter, Director, VIDO/InterVac, Canada

08:50-09:10 Title: Comparative Evaluation of

Vaccination Strategies Against Streptococcus Suis Infections in

Swine

Dr. Christoph Georg Baums, Professor, Institute for Microbiology,

Tieraerztliche Hochschule Hannover, Germany

09:10-09:30 Title: Quality Standards for foot-and-mouth

Disease (FMD) Vaccine: the Key Role of Highly Purified Antigens

Dr. Rodolfo Bellinzoni, Director of Operations, Biogénesis Bagó S.A,

Argentina

09:30-09:50 Title: The development of DNA Vaccine and

Adjuvant against Actinobacillus Pleuropneumoniae

Dr. WenJen Yang, Assistant Professor, National University of Kaohsiung,

Taiwan

09:50-10:10 Title: Gentamicin-Attenuated Leishmania

Infantum: Production of a Cellular Immune Response and Protection against

Experimental Visceral

Leishmaniasis Infection in Gogs

Dr. Hamid Daneshvar, Head of Department of Molecular Immunology, Medical

School of Kerman University, IranCoffee Break

10:10-10:30 Coffee Break

10:30-10:50 Title: Virus- and Cell-based Cancer

Vaccines for Agricultural and Companion Animals

Dr. Mark S. Parcells, Professor, University of Delaware, USA

10:50-11:10 Title: Vaccine Potential of Recombinant

Strains of Corynebacterium Pseudotuberculosis against Caseous

Lymphadenitis

Dr. Fernanda Alves Dorella, Post-doctoral, Federal University of Minas

Gerais, Brazil

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

11:10-10:10 Track 7-2: Livestock Vaccines

Chair: Dr. Potter, CEO and Director,

Vaccine and Infectious Disease Organization, Canada

Co-Chair: Dr. McVey,

Professor & Director, University of Nebraska, USA

11:10-11:30 Title: Genetic and Antigenic Variation

among Mannheimia Haemolytica Isolates of the Bovine Respiratory

Tract

Dr. McVey, Professor & Director, University of Nebraska,

USA

11:30-11:50 Title: Novel Vaccine Approaches to Control

E.coli O157:H7 in Cattle

Dr. Arvind Mahajan, Lecturer, Easter Bush Veterinary Research Centre,

UK

11:50-12:10 Title: The Reduction of Mortality Rate in a

Goat Breeding Farm in Sabah by Inactivated Recombinant Vaccine

Dr. M.Y. Sabri, Senior Lecturer, Universiti Putra Malaysia,

Malaysia

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

08:30-10:35 Track 7-3: Aquaculture Vaccines

Chair: Dr. Harry Klesius, Supervisory

Microbiologist & Research Leader, Aquatic Animal Health Research

Unit, USA

Co-Chair: Dr. W. Pridgeon,

Research Molecular Biologist, Aquatic Animal Health Research Unit,

USA

08:30-08:55 Title: Fish Vaccines �Current Status and

Future Challenges

Dr. Roar Gudding, Deputy Director, National veterinary institute,

Norway

08:55-09:20 Title: Molecular Approaches for Development

of Vaccines against Intracellular Fish Pathogens

Dr. Audun H. Nerland, Professor, Institute of Marine Research and

University of Bergen, Norway

09:20-09:45 Title:Streptococcus Iniae Vaccine

Dr. Harry Klesius, Supervisory Microbiologist & Research

Leader, Aquatic Animal Health Research Unit, USA

09:45-10:10 Title: Identification of Upregulated Genes

in a Modified Live Vaccine Strain of iella Ictaluri Compared to a

Virulent Parent Strain

and Characterization of Novel DNA Vaccine Candidates

Dr. W. Pridgeon, Research Molecular Biologist, Aquatic Animal

Health Research Unit, USA

10:10-10:35 Title: Bacterial Fish Vaccines -

Development, Production and Use

Dr. Nina Sandlund, Scientist, Institute of Marine Research,

Norway

Track 8: Vaccine Bioprocessing, Production and Manufacturing

Time and Place Co-Current Sessions and Activities

March 25, 2010

Thursday

08:30-11:50 Track 8-1: Better Tools for Bioprocessing

Vaccines

Chair: Dr. Liu, Director, Vaccine

Development, MedImmune,USA

Co-Chair: Dr. Kathleen L Hefferon,

Director, Operations of the Cornell Human Metabolic Research Unit,

Cornell University, USA

08:30-08:50 Keynote Speech:

Title: The Biosecurity, Production, and Quality Control of Specific

Pathogen Free (SPF) Eggs for Vaccine Production

Dr. Theodore Girshick, Director of Laboratory Operations, River

Avian Products and Services, USA

08:50-09:10 Title: International Regulations for

Vaccine Manufacturing: Perspectives on WHO, EU and FDA Expectations

Dr. M. Wheelwright, President, Strategic Manufacturing Worldwide,

Inc., USA

09:10-09:30 Title: Application of Process Analytic

Technology (PAT) in Vaccine Development: Using Modern Technologies to

Develop Modern Vaccines

Dr. Liu, Director of R & D,, Vaccine Development, MedImmune,

USA

09:30-09:50 Title: Industrial Purification Platform for

Various Flu and Flu like Particles

Dr. M. Y. Lim, Vice President Asia Region, BIA Separations,

Austria

09:50-10:10 Title: Direct and Real-time Sizing and

Counting of Viruses and VLPs in Liquids.

Dr. Malloy, Head, NanoSight Ltd., U.K.

10:10-10:30 Coffee Break

10:30-10:50 Title:Sabin-IPV Development for

Technology-Transfer Purposes: Initial Process Development and Clinical

Lot Production

Dr. Wilfried A. M. Bakker, Senior Scientist Viral Vaccines & Project

Leader, Netherlands Vaccine Institute, The Netherlands

10:50-11:10 Title: Biopharmaceuticals in Plants: Toward

the Next Century of Medicine

Dr. Kathleen L Hefferon, Director, Operations of the Cornell Human

Metabolic Research Unit, Cornell University, USA

11:10-11:30 Title: New Continuous Cell Substrates for

Vaccine Production: Development of New Assays to Detect Potential

Contaminants

Dr. Wisher, Senior Director, BioReliance, UK

11:30-11:50 Title: Foot-and-mouth Disease (FMD) Vaccine

Production: from a Local Market Supplier to a Major International Player;

a South American

Experience.

Dr. Rodolfo Bellinzoni, Director of Operations, Biogénesis Bagó S.A,

Argentina

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

13:30-14:45 Track 8-2: Creating Safe, Reliable, High

Yield Platforms for the Expression of Vaccine Antigens

Chair: Dr. W. Washabaugh, Senior

Director, Merck Research Laboratories, Merck & Co., Inc.,

USA

Co-Chair: Dr. Guohua Yue, President,

Antagen Biosciences, Inc., USA

13:30-13:55 Title: High-Performance Mammalian Cell

Expression System for Commercial Production of Therapeutic Proteins

Dr. Guohua Yue, President, Antagen Biosciences, Inc., USA

13:55-14:20 Title: Suspension-VERO Cell Cultures for

the Production of Viral Vaccines for Human Use

Dr. Marina Etcheverrigaray, Professor at the Universidad Nacional del

Litoral & Research Member of the National Research Council,

Argentina

14:20-14:45 Title: Baculovirus-silkworm Multigene

Expression Platform for Production of Virus –like Partticles Vaccine

Efficiently and Economically

Dr. Lunguang Yao, Vice Dean, Nanyang Normal University, China

Time and Place Co-Current Sessions and Activities

March 26, 2010

Friday

14:45-15:10 Track 8-3: Robust Bioprocessing of DNA

Vaccines

Chair: Dr. W. Washabaugh, Senior

Director, Merck Research Laboratories, Merck & Co., Inc.,

USA

Co-Chair: Dr. Guohua Yue, President,

Antagen Biosciences, Inc., USA

14:45-15:10 Title: DNA Vaccine Purification Process, a

Scale-up Study

Dr. Yongjian Zheng, Lead Application Scientist, GE Healthcare Life

Sciences, China

15:10-15:30 Coffee Break